01 October 2016: PREZCOBIX® (darunavir 800 mg and cobicistat 150 mg) tablets are now listed and approved on the Pharmaceutical Benefits Scheme (PBS), for patient co-payment subsidy. PREZCOBIX® is indicated for first starting treatment or for treatment experienced people living with HIV. PREZCOBIX® has been registered with the Australian Therapeutic Goods Administration (TGA) since 24 September 2015, awaiting this PBS approval for access.
Darunavir is an existing protease inhibitor (PREZISTA®) now combined into one tablet with a new boosting enhancer drug called cobicistat – effectively replacing ritonavir (Norvir®) which has been the traditional booster drug for many protease inhibitors. PREZCOBIX™ is a once-daily, fixed-dose antiretroviral combination tablet containing 800 mg of darunavir and 150 mg of cobicistat, to be taken orally in combination with other HIV medications (usually Truvada) and with food.
If you are presently taking a combination that includes darunavir (Prezista) boosted with ritonavir (Norvir) speak to your doctor whether a change to Prezcobix (combination single pill) might be relevant or recommended for you.
Consumer Medicine Information (CMI)